Market Research Logo

Next Generation Sequencing (NGS) Market Analysis by Application (HLA Testing, Prenatal Testing, Oncology, Idiopathic & Infectious Diseases), By Technology (Whole Genome Sequencing, Whole Exon Sequencing, Targeted Sequencing & Resequencing), By Workflow (N

Next Generation Sequencing (NGS) Market Analysis by Application (HLA Testing, Prenatal Testing, Oncology, Idiopathic & Infectious Diseases), By Technology (Whole Genome Sequencing, Whole Exon Sequencing, Targeted Sequencing & Resequencing), By Workflow (NGS Pre-Sequencing, NGS Sequencing, NGS Primary, Secondary & Tertiary Data Analysis), By End-use (Academic, Clinical Research, Hospitals & Clinics, Pharma & Biotech Entities) And Segment Forecasts To 2024

The global next generation sequencing market is anticipated to reach USD 14.0 billion by 2024, according to a new report by Grand View Research, Inc. Growing adoption of next generation sequencing techniques for prognosis and treatment monitoring of different chronic diseases such as cancer and other pathogenic infections is one of the high impact rendering driver for progress in this industry.

Application of genome and exome sequencing in the field of cancer research for companion diagnostics and biomarker development are expected to contribute towards the growth of this market throughout the forecast period.

Moreover, anticipated exponential decrease in the prices of genome sequence determination coupled with the launch of novel platforms and whole genome sequencers by major market players is expected to have a significant positive impact on the market penetration of various NGS applications.

Further key findings from the report suggest:

Out of the different applications served by NGS technology, Oncological applications accounted for the dominant share owing to phase-resolved and unambiguous results obtained by using single assay systems, and analysis program. However, the use of HLA typing in gaining insights for organ rejection, organ matching, and immune disorders by understanding intricacies of less accessible genetic sequence structures is anticipated to provide scientists with new avenues for medical research over the forecast period.

Depending on the approaches by which the number of base pairs can be determined in a given sequencing read cycle, the technologies can be segmented as targeted sequencing & resequencing, whole genome, and whole exome sequencing. Targeted resequencing dominated the market with a revenue share of over 70%owing to the benefits associated with implementation of the technique such as lower turnaround time and more manageable data sets.

Amongst workflow steps involved, NGS data analysis encompasses the final phase of data storage and analysis of large amounts of sequenced data which is generated. This segment is expected to witness growth in demand in tandem to growth in demand for NGS through to 2024.

Academic R&D usage of NGS accounted for the largest share with respect to market revenue by end uses and is anticipated to maintain its dominance owing to higher adoption of this technology and platforms in university projects related to molecular, genetic & proteomic biology, and drug discovery/development.

North America dominated the market in 2015, generating over 46% of total revenue. Presence of the key participants operating in this region which are involved in development of novel algorithms and software in order to enhance data analysis is attributive for the large share of North America in industrial revenue. Demand for whole genome sequencing services for disease progression monitoring is also expected to drive industrial progress.

Asia Pacific is estimated to witness the fastest growth over the forecast period owing to the expected routing of a considerable portion of whole genome sequencing requirements through a couple of the world’s largest sequencing facilities present in the region and potential presence of unmet demands by the research institutions with respect to sequence determination techniques and data analysis algorithms.

Key players operating in the next generation sequencing market include Illumina Inc., Agilent Technologies, Biomatters Ltd., Bgi (Beijing Genomics Institute), Pacific Biosciences, Dnastar., Clc Bio (Qiagen), 454 Life Science Corp. (Roche), GATC Biotech Ag, Knome Inc., Life Technologies Corp. (Thermo Fischer Scientific), Genomatix Software GmbH, Macrogen., Partek., Oxford Nanopore Technologies Ltd., and Perkin Elmer.

This market is witnessing high level of competitive rivalry, consequently leading to constant endeavors carried out by the prominent players in order to maintain the position and share in the industry. These endeavors include launch of novel products, providing services and products in different economies across the globe, broadening of the product portfolio with respect to various application areas, and acquisition of the smaller entities in attempts to enhance product portfolio. For instance, Qiagen acquired solutions unit of Enzymatics in order to enhance the product portfolio with respect to reagents needed in preparatory steps.


Chapter 1 Research Methodology & Scope
1.1 Region Wise Market Calculation
1.1.1 Region Wise Market: Base Estimates
1.1.2 Global Market: CAGR Calculation
1.2 Region based segment share calculation
1.3 List of Secondary Sources
Chapter 2 Executive Summary
Chapter 3 Market Snapshot
Chapter 4 Market Variables, Trends& Scope
4.1 Market segmentation& scope
4.1.1 Market Driver Analysis
4.1.1.1 Exponentially decreasing costs for genetic sequencing
4.1.1.2 Growing related advancement of personalized medicine
4.1.1.3 Growing healthcare expenditure triggering development of effective PM diagnostic & therapeutic procedure for cancer
4.1.1.4 Increasing prevalence of cancer
4.1.1.5 Rise in competition amongst prominent market entities
4.1.2 Market Restraint Analysis
4.1.2.1 Non-value based NGS reimbursement policy
4.2 Penetration & growth prospect mapping
4.3 Next Generation Sequencing - SWOT Analysis, By Factor (political & legal, economic and technological)
4.4 Industry Analysis - Porter’s
Chapter 5 Market Categorization 1: Applications Estimates & Trend Analysis
5.1 Next generation sequencing market: application movement analysis
5.2 HLA Testing
5.2.1 Global HLA testing market, 2013 - 2024 (USD Million)
5.3 Prenatal Testing
5.3.1 Global prenatal testing market, 2013 - 2024 (USD Million)
5.4 Oncology
5.4.1 Global oncology market, 2013 - 2024 (USD Million)
5.5 Idiopathic Diseases
5.5.1 Global idiopathic diseases market, 2013 - 2024 (USD Million)
5.6 Infectious Diseases
5.6.1 Global infectious diseases market, 2013 - 2024 (USD Million)
Chapter 6 Market Categorization 2: Technology Estimates & Trend Analysis
6.1 Next generation sequencing market: Technology movement analysis
6.2 Targeted Sequencing & Resequencing
6.2.1 Global targeted sequencing & resequencing market, 2013 - 2024 (USD Million)
6.3 Whole Genome Sequencing
6.3.1 Global whole genome sequencing market, 2013 - 2024 (USD Million)
6.4 Whole Exome Sequencing
6.4.1 Global whole exome sequencing market, 2013 - 2024 (USD Million)
Chapter 7 Market Categorization 3: Workflow Estimates & Trend Analysis
7.1 Next generation sequencing market: workflow movement analysis
7.2 NGS Pre-Sequencing
7.2.1 Global NGS pre-sequencing market, 2013 - 2024 (USD Million)
7.3 NGS Sequencing
7.3.1 Global NGS sequencing market, 2013 - 2024 (USD Million)
7.4 NGS Data Analysis
7.4.1 Global NGS data analysis 2013 - 2024 (USD Million)
7.4.2 NGS Primary Data Analysis
7.4.2.1 Global NGS primary data analysis market, 2013 - 2024 (USD Million)
7.4.3 NGS Secondary Data Analysis
7.4.3.1 Global NGS secondary data analysis, 2013 - 2024 (USD Million)
7.4.4 NGS Tertiary Data Analysis
7.4.4.1 Global NGS tertiary data analysis services market, 2013 - 2024 (USD Million)
Chapter 8 Market Categorization 4: End-use Estimates & Trend Analysis
8.1 Next generation sequencing market: End-use movement analysis
8.2 Academic Research
8.2.1 Global academic research market, 2013 - 2024 (USD Million)
8.3 Clinical Research
8.3.1 Global clinical research market, 2013 - 2024 (USD Million)
8.4 Hospitals & Clinics
8.4.1 Global hospitals & clinics market 2013 - 2024 (USD Million)
8.5 Pharma & Biotech Entities
8.5.1 Global pharma & biotech entities market, 2013 - 2024 (USD Million)
8.6 Other Users
8.6.1 Global other users market, 2013 - 2024 (USD Million)
Chapter 9 Market Categorization 4: Regional Estimates & Trend Analysis, by Service Type, Sector & Application
9.1 Next generation sequencing market share by region, 2015 & 2024
9.2 North America
9.2.1 North America next generation sequencing market, 2013 - 2024 (USD Million)
9.2.2 U.S.
9.2.2.1 U.S. next generation sequencing market, 2013 - 2024 (USD Million)
9.2.3 Canada.
9.2.3.1 Canada next generation sequencing market, 2013 - 2024 (USD Million)
9.3 Europe
9.3.1 Europe next generation sequencing market, 2013 - 2024 (USD Million)
9.3.2 Germany.
9.3.2.1 Germany next generation sequencing market, 2013 - 2024 (USD Million)
9.3.3 UK.
9.3.3.1 UK next generation sequencing market, 2013 - 2024 (USD Million)
9.4 Asia Pacific.
9.4.1 Asia Pacific next generation sequencing market, 2013 - 2024 (USD Million)
9.4.2 Japan.
9.4.2.1 Japan next generation sequencing market, 2013 - 2024 (USD Million)
9.4.3 China.
9.4.3.1 China next generation sequencing market, 2013 - 2024 (USD Million)
9.5 Latin America.
9.5.1 Latin America next generation sequencing market, 2013 - 2024 (USD Million)
9.5.2 Brazil.
9.5.2.1 Brazil next generation sequencing market, 2013 - 2024 (USD Million)
9.6 Middle East & Africa.
9.6.1 Middle East & Africa next generation sequencing market, 2013 - 2024 (USD Million)
9.6.2 South Africa
9.6.2.1 South Africa next generation sequencing market, 2013 - 2024 (USD Million)
Chapter 10 Competitive Landscape
10.1 Strategy framework
10.2 Market participation categorization
10.3 Company Profiles
10.3.1 Illumina Incorporated
10.3.1.1 Company Overview
10.3.1.2 Financial Performance
10.3.1.3 Product Benchmarking
10.3.1.4 Strategic Initiatives
10.3.2 454 Life Sciences
10.3.2.1 Company Overview
10.3.2.2 Financial Performance
10.3.2.3 Product Benchmarking
10.3.2.4 Strategic Initiatives
10.3.3 Agilent Technologies
10.3.3.1 Company Overview
10.3.3.2 Financial Performance
10.3.3.3 Product Benchmarking
10.3.3.4 Strategic Initiatives
10.3.4 Knome Inc.
10.3.4.1 Company Overview
10.3.4.2 Financial Performance
10.3.4.3 Product Benchmarking
10.3.4.4 Strategic Initiatives
10.3.5 Genomatix Software GmbH
10.3.5.1 Company Overview
10.3.5.2 Financial Performance
10.3.5.3 Product Benchmarking
10.3.5.4 Strategic Initiatives
10.3.6 GATC Biotech Ag
10.3.6.1 Company Overview
10.3.6.2 Financial Performance
10.3.6.3 Product Benchmarking
10.3.6.4 Strategic Initiatives
10.3.7 Oxford Nanopore Technologies Ltd.
10.3.7.1 Company Overview
10.3.7.2 Financial Performance
10.3.7.3 Product Benchmarking
10.3.7.4 Strategic Initiatives
10.3.8 Macrogen Inc.
10.3.8.1 Company Overview
10.3.8.2 Financial Performance
10.3.8.3 Product Benchmarking
10.3.8.4 Strategic Initiatives
10.3.9 Life Technologies Corp.
10.3.9.1 Company Overview
10.3.9.2 Financial Performance
10.3.9.3 Product Benchmarking
10.3.9.4 Strategic Initiatives
10.3.10 DNASTAR Inc.
10.3.10.1 Company Overview
10.3.10.2 Financial Performance
10.3.10.3 Product Benchmarking
10.3.10.4 Strategic Initiatives
10.3.11 Biomatters Ltd.
10.3.11.1 Company Overview
10.3.11.2 Financial Performance
10.3.11.3 Product Benchmarking
10.3.11.4 Strategic Initiatives
10.3.12 Life CLC Bio
10.3.12.1 Company Overview
10.3.12.2 Financial Performance
10.3.12.3 Product Benchmarking
10.3.12.4 Strategic Initiatives
10.3.13 BGI
10.3.13.1 Company Overview
10.3.13.2 Financial Performance
10.3.13.3 Product Benchmarking
10.3.13.4 Strategic Initiatives
10.3.14 Qiagen NV
10.3.14.1 Company Overview
10.3.14.2 Financial Performance
10.3.14.3 Product Benchmarking
10.3.14.4 Strategic Initiatives
10.3.15 Perkin Elmer, Inc.
10.3.15.1 Company Overview
10.3.15.2 Financial Performance
10.3.15.3 Product Benchmarking
10.3.15.4 Strategic Initiatives
10.3.16 Pacific Bioscience, Inc.
10.3.16.1 Company Overview
10.3.16.2 Financial Performance
10.3.16.3 Product Benchmarking
10.3.16.4 Strategic Initiatives
10.3.17 Partek, Inc.
10.3.17.1 Company Overview
10.3.17.2 Financial Performance
10.3.17.3 Product Benchmarking
10.3.17.4 Strategic Initiatives

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report